Literature DB >> 31779685

Protocols-more structure, less 'Wuthering Heights'.

Shaun Treweek1.   

Abstract

Entities:  

Mesh:

Year:  2019        PMID: 31779685      PMCID: PMC6883621          DOI: 10.1186/s13063-019-3865-7

Source DB:  PubMed          Journal:  Trials        ISSN: 1745-6215            Impact factor:   2.279


× No keyword cloud information.
Many years ago I went through a phase of reading classic novels, books written by authors we’ve all heard of who are now dead. I ended up keeping just one of these: Wuthering Heights. Emily Brontë’s novel centres on the fiery love between man of mystery Heathcliff and Catherine Earnshaw, the latter of whom inconveniently dies halfway through the book. On Catherine’s death, Heathcliff’s desperate response is: And I pray one prayer—I repeat it till my tongue stiffens—Catherine Earnshaw, may you not rest as long as I am living! You said I killed you—haunt me, then!…Be with me always—take any form—drive me mad! only do not leave me in this abyss, where I cannot find you! Gripping stuff. The reason for raising this topic is that finding this quote in the book was hard work despite my knowing it was in there somewhere. The presentation format of Wuthering Heights does not make finding things easy; you’re supposed to start at the beginning and keep going.1 For a novel this hardly matters; few people pick up Wuthering Heights just to find out what Heathcliff said when Catherine died. But it does matter for trial protocols. People do look at these protocols just to find out how the randomisation was done, or what the primary outcome is, or how adverse events will be collected. Even when information is present in a protocol, finding it can be frustratingly difficult. This is a sorry state of affairs precisely because we do dip in and out of protocols so much. The Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) checklist [1] recommends what should be in a protocol but not where it should be. Consequently, navigating a protocol can be maddening. Apart from wasting everyone’s time, it makes it easier for methodological weakness, error and poor practice to pass unseen. In 2015 our late founding editor Doug Altman suggested that we should make greater use of structure in research articles [2]. Structured information of the sort seen in trial registries is in contrast to what I think of as the ‘Wuthering Heights’ approach to research reporting: material written so that you have to start at the beginning and keep going. But we are not writing novels. We are providing information that should be clear, complete and, crucially, easy to navigate. To make protocols less ‘Wuthering Heights’, Trials is experimenting with a new way to structure the protocol for a randomised trial. The simple innovation is to include all the SPIRIT headings and item identifiers in the protocol itself. We then know what has to be in the protocol and where to put it. We can see—quickly—when information is missing. If you, the authors, want to add additional headings, specific to your trial, go ahead. If you’d like to add the pdf of the protocol you submitted to your ethics committee (in any language) as a supplementary document, please do. We’ve reformatted the protocol for the AMBER trial, which was published in Trials in 2017 [3], into this new structured format so that you can compare it to the original; see Additional file 1. A newly submitted protocol has also used this format [4] (https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-019-3500-7). In both cases you’ll see that it’s not so different to what we’re all used to. These protocols do, however, have something written under all 51 items of the SPIRIT checklist, which was not quite the case for the AMBER protocol that had been published already. To make things easier, we’ve created a template for this new format that contains both SPIRIT and Trials guidance in one place: https://trialsjournal.biomedcentral.com/submission-guidelines/preparing-your-manuscript/study-protocol/structured-study-protocol-template. We’ve changed the ordering of some SPIRIT items in the template to make it flow better, but all the original SPIRIT item identifiers are there. If what matters to you is how harms are collected and assessed, searching for ‘{22}’ in one of these structured protocols will always land you in the right place. Typing ‘{6b}’ will always take you to the rationale behind the comparators. In short, readers can search the headings, find what is needed and ignore the rest if they want to. Trials is not making use of this structure mandatory, and we will continue to consider protocols submitted in other formats. All will continue to be checked against the SPIRIT checklist. But we think the new structured approach will improve reporting (as it did for the previously published AMBER protocol) and improve publication times because the cross-check with SPIRIT will be much easier. The protocol is likely to be a more useful tool for those inside and outside the trial team who need to refer to it. As Doug wrote in 2015, despite improved communication about trials being part of the editorial that launched Trials, there hasn’t been much activity on this theme [2]. Well, here’s to structured protocols. Additional file 1. The AMBER protocol after reformatting using the structured protocol template.
  4 in total

1.  SPIRIT 2013 statement: defining standard protocol items for clinical trials.

Authors:  An-Wen Chan; Jennifer M Tetzlaff; Douglas G Altman; Andreas Laupacis; Peter C Gøtzsche; Karmela Krleža-Jerić; Asbjørn Hróbjartsson; Howard Mann; Kay Dickersin; Jesse A Berlin; Caroline J Doré; Wendy R Parulekar; William S M Summerskill; Trish Groves; Kenneth F Schulz; Harold C Sox; Frank W Rockhold; Drummond Rennie; David Moher
Journal:  Ann Intern Med       Date:  2013-02-05       Impact factor: 25.391

2.  Making research articles fit for purpose: structured reporting of key methods and findings.

Authors:  Douglas G Altman
Journal:  Trials       Date:  2015-02-20       Impact factor: 2.279

3.  Abdominal massage for neurogenic bowel dysfunction in people with multiple sclerosis (AMBER - Abdominal Massage for Bowel Dysfunction Effectiveness Research): study protocol for a randomised controlled trial.

Authors:  Doreen McClurg; Kirsteen Goodman; Suzanne Hagen; Fional Harris; Sean Treweek; Anton Emmanuel; Christine Norton; Maureen Coggrave; Selina Doran; John Norrie; Peter Donnan; Helen Mason; Sarkis Manoukian
Journal:  Trials       Date:  2017-03-29       Impact factor: 2.279

4.  Reducing Asthma Attacks in Children using Exhaled Nitric Oxide as a biomarker to inform treatment strategy: a randomised trial (RAACENO).

Authors:  S Turner; S C Cotton; C D Emele; R Thomas; S Fielding; E A Gaillard; J C de Jongste; H Morgan; A R Neilson; J Norrie; M Pijnenburg; D Price; M Thomas
Journal:  Trials       Date:  2019-10-04       Impact factor: 2.279

  4 in total
  3 in total

1.  Auricular acupressure for adverse events following immunization related to COVID-19 vaccine injection: study protocol for a multicenter, three-arm, blinded randomized controlled trial.

Authors:  Qinwei Fu; Hui Xie; Li Zhou; Xinrong Li; Yang Liu; Min Liu; Chaoyu Wang; Xiaocen Wang; Zhiqiao Wang; Jinfan Tang; Huan Xiao; Zhiyong Xiao; Jing Zhou; Chengzhi Feng; Li Wang; Zhimin Ao; Xi Chen; Chang Su; Xuanyu Wu; Maolan Zhao; Sihan Hu; Hanwen Lin; Jiali Huang; Guo Xu; Qinxiu Zhang; Luyun Jiang
Journal:  Trials       Date:  2021-11-27       Impact factor: 2.728

2.  The SPIRIT Checklist-lessons from the experience of SPIRIT protocol editors.

Authors:  Riaz Qureshi; Alexander Gough; Kirsty Loudon
Journal:  Trials       Date:  2022-04-27       Impact factor: 2.728

3.  A longitudinal assessment of trial protocols approved by research ethics committees: The Adherance to SPIrit REcommendations in the UK (ASPIRE-UK) study.

Authors:  Benjamin Speich; Ayodele Odutayo; Nicholas Peckham; Alexander Ooms; Jamie R Stokes; Ramon Saccilotto; Dmitry Gryaznov; Belinda von Niederhäusern; Bethan Copsey; Douglas G Altman; Matthias Briel; Sally Hopewell
Journal:  Trials       Date:  2022-07-27       Impact factor: 2.728

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.